Dark Forest Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Dark Forest Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,813	Closed	-$65.7K	–	1381
2023 Q1	$65.7K	Buy	+1,813	New	+$69.7K	0.02%	780
2022 Q2	–	Sell	-366	Closed	-$11K	–	1352
2022 Q1	$11K	Buy	+366	New	+$11.2K	﹤0.01%	983
2021 Q3	–	Sell	-768	Closed	-$24K	–	1536
2021 Q2	$24K	Buy	+768	New	+$23.5K	0.01%	546

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dark Forest Capital Management's SUPN Position: Q2 2023 in Review

Dark Forest Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2023, closing a stake of 1,813 shares — an estimated $65.7K sold.

Dark Forest Capital Management first reported a position in SUPN in Q2 2021 and held it in 3 quarters. The position peaked at $65.7K in Q1 2023. 249 funds tracked by Wall St. Rank hold SUPN as of Q2 2023.

Dark Forest Capital Management reported no remaining Supernus Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Dark Forest Capital Management sold 1,813 Supernus Pharmaceuticals shares in Q2 2023, an estimated $65.7K.
Dark Forest Capital Management first reported a position in Supernus Pharmaceuticals in Q2 2021 and held it in 3 quarters.
Dark Forest Capital Management's Supernus Pharmaceuticals position peaked at $65.7K in Q1 2023.
249 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2023.

Based on Dark Forest Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.